[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
[^7]
[^8]
EZH2 is a human gene. Variants in EZH2 have been implicated in Sotos Syndrome, Alzheimer's Disease, Parkinson's Disease. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
NSD1 encodes a histone lysine methyltransferase of the nuclear receptor SET domain (NSD) family that catalyzes mono- and dimethylation of histone H3 at lysine 36 (H3K36me1/2). H3K36 methylation is a transcription-associated activating mark that is deposited within gene bodies during active transcription and serves as a critical epigenetic signal for multiple downstream processes.
NSD1 is a large (2696 amino acid) multidomain protein containing:
- SET domain: Catalytic methyltransferase domain responsible for H3K36 methylation
- PWWP domain: Reads existing H3K36me marks, enabling spreading of the modification along gene bodies
- PHD fingers (5x): Recognize various histone modifications for chromatin targeting
- Nuclear receptor interaction domains (NID+/NID-): Allow NSD1 to interact with nuclear hormone receptors, integrating hormonal signaling with chromatin modification
NSD1 regulates neural biology through multiple mechanisms:
- Gene body methylation: H3K36me2 deposited by NSD1 in gene bodies prevents aberrant intragenic transcription initiation, ensuring accurate expression of large neural genes (many neuronal genes are exceptionally long, up to >1 Mb)
- Alternative splicing regulation: H3K36me2/3 marks recruit splicing factors to pre-mRNAs during co-transcriptional processing; NSD1 loss causes widespread splicing dysregulation in neurons
- DNA methylation guidance: H3K36me2 recruits the DNMT3A/3B DNA methyltransferases, directing DNA methylation to actively transcribed regions. NSD1 loss causes DNA hypomethylation at thousands of genomic sites
- Histone crosstalk: H3K36me2 antagonizes PRC2-mediated H3K27me3 deposition, maintaining the boundary between active and repressed chromatin domains
- DNA damage response: NSD1-mediated H3K36me2 facilitates recruitment of DNA repair factors to damaged chromatin in postmitotic neurons
Haploinsufficiency of NSD1 causes Sotos syndrome (OMIM 117550), characterized by childhood overgrowth, macrocephaly, distinctive facial features, and intellectual disability. The neurological features of Sotos syndrome are particularly informative for understanding NSD1's neural functions:
- Intellectual disability: 80-90% of patients have mild-to-moderate ID, reflecting NSD1's role in neuronal gene regulation
- Behavioral abnormalities: ADHD, anxiety, ASD features, and poor social skills are common
- Seizures: Present in ~25% of patients
- Brain structural anomalies: Ventriculomegaly, thinning of the corpus callosum, and periventricular leukomalacia
- Advanced bone age: Reflecting NSD1's role in growth regulation
Most Sotos cases result from intragenic NSD1 mutations (point mutations, small insertions/deletions) or 5q35 microdeletions encompassing NSD1.
NSD1 expression declines in aging and AD brain, contributing to epigenomic dysregulation:
- H3K36me2 loss: Reduced NSD1 activity leads to global decrease of H3K36me2, causing aberrant intragenic transcription and cryptic transcription initiation at thousands of neuronal genes
- DNA methylation erosion: NSD1-dependent DNA methylation marks are lost, contributing to the widespread DNA methylation changes observed in AD brain
- Polycomb spreading: Without H3K36me2 boundaries, PRC2-mediated H3K27me3 (EZH2) can spread into actively transcribed neuronal genes, silencing them
- Splicing dysregulation: Loss of NSD1-dependent H3K36me2 marks disrupts co-transcriptional splicing of large neuronal genes, producing aberrant transcripts
- Tau-related effects: NSD1 regulates expression of MAPT and tau kinase genes; its loss may alter tau isoform ratios
In PD substantia nigra:
- NSD1 protein levels are reduced in dopaminergic neurons preceding cell death
- Loss of H3K36me2 at dopaminergic identity genes (TH, DDC) contributes to dedifferentiation of DA neurons
- NSD1 interacts with nuclear receptors including NURR1/NR4A2, a master regulator of dopaminergic neuron specification; NSD1 loss impairs NURR1-mediated transcription
- Mitochondrial gene expression is regulated by NSD1-deposited H3K36me2 at nuclear-encoded mitochondrial genes
NSD1 mutations are found in ~1% of ASD cases. The H3K36me2/DNA methylation axis controlled by NSD1 is critical for regulating genes involved in synaptic development, neuronal migration, and cortical circuit formation.
NSD1 is broadly expressed but shows enrichment in developing and adult brain:
- Cerebral cortex — High expression in excitatory neurons of all layers; particularly enriched in layers II/III and V
- Hippocampus — Strong expression in CA1/CA3 pyramidal neurons and dentate gyrus; required for learning-related gene regulation
- Cerebellum — Expressed in Purkinje cells and granule neurons
- Substantia nigra — Present in TH-positive dopaminergic neurons
- During development — NSD1 is highly expressed in neural progenitors and increases further upon neuronal differentiation
NSD1 expression decreases with normal aging, with accelerated decline in neurodegenerative conditions. The protein is exclusively nuclear, consistent with its role as a chromatin modifier.
¶ Common Variants and Risk Alleles
| Variant |
Type |
Association |
Effect |
| 5q35 microdeletion |
CNV |
Sotos syndrome |
Complete NSD1 loss (haploinsufficiency) |
| p.R1952W |
Missense |
Sotos syndrome |
Disrupted SET domain catalytic activity |
| p.Y1971C |
Missense |
Sotos syndrome/ASD |
Impaired H3K36 methylation |
| rs2304620 |
Regulatory |
Cognitive aging (suggestive) |
Altered NSD1 expression in brain |
| p.C2027Y |
Missense |
Weaver-like overgrowth |
Gain of function |
- NSD1 activators: Small molecules that enhance residual NSD1 methyltransferase activity could restore H3K36me2 levels in aging neurons, potentially slowing epigenomic deterioration
- EZH2 inhibitors: Since NSD1 loss allows aberrant PRC2 (EZH2) spreading, EZH2 inhibitors could rescue inappropriate H3K27me3 accumulation at neuronal genes
- DNMT3A/B modulation: Compensating for NSD1-dependent DNA methylation loss through targeted DNMT3A/B activation
- Dietary methyl donors: Folate, SAM, and betaine supplementation could partially offset methylation deficits in NSD1-deficient states
- Antisense oligonucleotides: For Sotos patients with nonsense mutations, ASO approaches targeting nonsense-mediated decay could restore NSD1 protein levels